CA3085951C - Methods of treatment of hypertriglyceridemia - Google Patents
Methods of treatment of hypertriglyceridemia Download PDFInfo
- Publication number
- CA3085951C CA3085951C CA3085951A CA3085951A CA3085951C CA 3085951 C CA3085951 C CA 3085951C CA 3085951 A CA3085951 A CA 3085951A CA 3085951 A CA3085951 A CA 3085951A CA 3085951 C CA3085951 C CA 3085951C
- Authority
- CA
- Canada
- Prior art keywords
- week
- hdl
- pemafibrate
- subject
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609048P | 2017-12-21 | 2017-12-21 | |
| US62/609,048 | 2017-12-21 | ||
| PCT/US2018/066976 WO2019126597A1 (en) | 2017-12-21 | 2018-12-20 | Methods of treatment of hypertrigl yceridemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3085951A1 CA3085951A1 (en) | 2019-06-27 |
| CA3085951C true CA3085951C (en) | 2022-10-11 |
Family
ID=66995099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3085951A Active CA3085951C (en) | 2017-12-21 | 2018-12-20 | Methods of treatment of hypertriglyceridemia |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190224169A1 (enExample) |
| EP (1) | EP3727376A4 (enExample) |
| JP (2) | JP2021506907A (enExample) |
| CN (1) | CN111741753A (enExample) |
| AU (1) | AU2018393119B2 (enExample) |
| CA (1) | CA3085951C (enExample) |
| MY (1) | MY205171A (enExample) |
| SG (1) | SG11202005850VA (enExample) |
| WO (1) | WO2019126597A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024014524A1 (ja) * | 2022-07-15 | 2024-01-18 | 興和株式会社 | 血中ｌｄｌコレステロール低下剤 |
| WO2024167964A1 (en) * | 2023-02-08 | 2024-08-15 | Kowa Company, Ltd. | Methods of treating and preventing peripheral artery disease |
| WO2025069226A1 (ja) * | 2023-09-26 | 2025-04-03 | 興和株式会社 | ペマフィブラートを含有する医薬 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2535749C (en) * | 2003-09-03 | 2011-11-01 | Kowa Co., Ltd. | Ppar activating compound and pharmaceutical composition containing same |
| TWI407955B (zh) * | 2007-03-29 | 2013-09-11 | Kowa Co | 高脂血症之預防及／或治療劑 |
| EP2902025B1 (en) * | 2012-09-27 | 2019-08-07 | Kowa Company Ltd. | Therapeutic agent for dyslipidemia |
| CN106470675A (zh) * | 2014-06-26 | 2017-03-01 | 西玛贝医药公司 | 严重高甘油三酯血症的治疗 |
| TWI691331B (zh) * | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
| RS61403B1 (sr) * | 2016-07-29 | 2021-02-26 | Kowa Co | Postupci prevencije kardiovaskularnih događaja u populacijama sa dislipidemijom sa rezidualnim rizikom |
-
2018
- 2018-12-20 JP JP2020534340A patent/JP2021506907A/ja active Pending
- 2018-12-20 EP EP18892061.5A patent/EP3727376A4/en active Pending
- 2018-12-20 CN CN201880089648.7A patent/CN111741753A/zh active Pending
- 2018-12-20 WO PCT/US2018/066976 patent/WO2019126597A1/en not_active Ceased
- 2018-12-20 MY MYPI2020003113A patent/MY205171A/en unknown
- 2018-12-20 US US16/227,440 patent/US20190224169A1/en not_active Abandoned
- 2018-12-20 CA CA3085951A patent/CA3085951C/en active Active
- 2018-12-20 SG SG11202005850VA patent/SG11202005850VA/en unknown
- 2018-12-20 AU AU2018393119A patent/AU2018393119B2/en active Active
-
2023
- 2023-11-01 JP JP2023187862A patent/JP2023181451A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023181451A (ja) | 2023-12-21 |
| CA3085951A1 (en) | 2019-06-27 |
| EP3727376A1 (en) | 2020-10-28 |
| AU2018393119B2 (en) | 2022-08-25 |
| MY205171A (en) | 2024-10-04 |
| WO2019126597A1 (en) | 2019-06-27 |
| JP2021506907A (ja) | 2021-02-22 |
| EP3727376A4 (en) | 2021-07-21 |
| US20190224169A1 (en) | 2019-07-25 |
| SG11202005850VA (en) | 2020-07-29 |
| CN111741753A (zh) | 2020-10-02 |
| AU2018393119A1 (en) | 2020-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210069158A1 (en) | Methods of Preventing Occurrence of Cardiovascular Events | |
| Chan et al. | Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients | |
| Ballantyne et al. | Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non–HDL cholesterol (from the SEACOAST I Study) | |
| JP2023181451A (ja) | 高トリグリセライド血症の治療方法 | |
| Song et al. | Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation | |
| Friedland et al. | The cardiovascular effects of peroxisome proliferator-activated receptor agonists | |
| JP2018536710A (ja) | 混合型脂質異常症の治療 | |
| Bays et al. | Icosabutate for the treatment of very high triglycerides: a placebo-controlled, randomized, double-blind, 12-week clinical trial | |
| US11446282B2 (en) | Methods of treating mixed dyslipidemia and hypertriglycertdemia | |
| Wei et al. | Betel nut chewing associated with increased risk of arterial stiffness | |
| Chen et al. | Efficacy and tolerability of coenzyme A vs pantethine for the treatment of patients with hyperlipidemia: A randomized, double-blind, multicenter study | |
| TWI741379B (zh) | 藥物組成物與包含膽固醇酯轉移蛋白抑制劑和HMG CoA還原酶抑制劑的治療組合 | |
| Stefanutti et al. | Hypertriglyceridaemia, postprandial lipaemia and non-HDL cholesterol | |
| Wang et al. | Efficacy and safety of Huzhang Granule, a compound Chinese herbal medicine, for acute gouty arthritis: a double-blind, randomized controlled trial | |
| Zeni Klafke et al. | Biomarkers of subclinical atherosclerosis and natural products as complementary alternative medicine | |
| Aguilar-Salinas et al. | Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study | |
| Hobbs | Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control | |
| US20230092776A1 (en) | Methods of treating mixed dyslipidemia and hypertriglyceridemia | |
| Roy et al. | Significant reduction of elevated triglycerides and liver fibrosis in diabetic dyslipidemia with saroglitazar: A case report | |
| Insull Jr et al. | Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia | |
| Sharma et al. | Saroglitazar, a novel cardiometabolic agent for diabetic dyslipidemia–A Review | |
| Yoon et al. | Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia | |
| Basuny et al. | Evaluating the Safety and Efficacy of the traditional use of Turmeric powder as Antihypertensive in Elderly | |
| Tonstad et al. | The dual peroxisome proliferator–activated receptor α/γ agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin | |
| Malekmakan et al. | Efficacy and safety of turmeric dietary supplementation on proteinuria in CKD: a systematic review and meta-analysis of RCT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200615 |
|
| EEER | Examination request |
Effective date: 20200615 |